NASDAQ$PROK
ProKidney Corp · Q2 2026 earnings
Q2 2026 earnings · · During market hours · Investor relations
Briefing
ProKidney Corp reported Q2 2026 financial results on August 10, 2026, highlighting clinical progress and a net loss of $46.4 million.
ProKidney, a clinical-stage cell therapy company, reported no revenue for the quarter ended June 30, 2026. The company posted a net loss of $46.4 million ($0.15 per share) and ended the period with $181.6 million in cash, cash equivalents, and marketable securities. Key business updates included completing enrollment for the PROACT 1 accelerated approval analysis with topline results expected in Q2 2027.
- Completed enrollment for Phase 3 PROACT 1 accelerated approval efficacy analysis; topline eGFR slope results anticipated in Q2 2027.
- R&D expenses increased to $36.1 million from $25.9 million YoY due to PROACT 1 study costs.
- Ended Q2 with $181.6 million in liquidity, supporting operations into mid-2027.
- Net loss of $46.4 million ($0.15 per share) compared to $37.0 million in Q2 2025.
Headline financials
Revenue & EPS history
ProKidney · Revenue · Quarterly
$0
Forward guidance
Cash runway into mid-2027; PROACT 1 full enrollment in H2 2026 and topline in Q2 2027 for accelerated approval path.
Tailwinds
- Strong liquidity position supports ongoing Phase 3 trial.
- Clinical milestones on track for potential regulatory progress.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports
-2.4%
Avg return
Earnings day
-3.0%
Avg return
5 days after
+2.6%
Avg return
30 days after
25%
4 / 16 earnings
Positive
+18.0%
Q1 2024
Best reaction
-13.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -2.3% | -1.2% | -4.7% | |
| Q4 2025 | -4.0% | -8.9% | +2.3% | |
| Q3 2025 | -8.8% | -16.6% | -24.9% | |
| Q2 2025 | -0.9% | +4.7% | +32.2% | |
| Q1 2025 | -6.0% | -9.3% | -1.4% | |
| Q4 2024 | -6.8% | -7.7% | -23.9% | |
| Q3 2024 | -3.7% | -21.2% | -12.6% | |
| Q2 2024 | -0.5% | +9.1% | +11.5% | |
| Q1 2024 | +18.0% | +50.2% | +22.2% | |
| Q4 2023 | -4.1% | +8.9% | +39.7% | |
| Q3 2023 | -13.1% | -24.4% | +20.0% | |
| Q2 2023 | +0.4% | -14.5% | -37.5% | |
| Q1 2023 | +1.2% | +8.1% | +34.0% | |
| Q4 2022 | -9.8% | -12.9% | -24.6% | |
| Q3 2022 | -4.7% | -14.8% | -23.6% | |
| Q2 2022 | +7.3% | +2.7% | +32.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro